Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multiple antimicrobial resistant bacterial isolates

ABSTRACT: Bacterial Isolate Assemblies for Microbiota Restoration Reduces Antibiotic Resistant Bacteria Gut Colonization in Patients with Recurrent Clostridioides difficile Infection from the Open-Label PUNCH CD Study, Nov 01 '20

PROVIDER: PRJNA693986 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	JAHLQX01.dat.gz	Other
	JAHLQX01.fasta.gz	Fasta.gz
	JAHLQX01.master.dat	Other
	JAHLQY01.dat.gz	Other

Items per page:

1 - 5 of 37

Similar Datasets

Project description:Bacterial Isolate Assemblies for Microbiota Restoration Reduces Antibiotic Resistant Bacteria Gut Colonization in Patients with Recurrent Clostridioides difficile Infection from the Open-Label PUNCH CD Study, Nov 04 '20

| PRJNA694154 | ENA

Project description:Microbiota Restoration Reduces Antibiotic Resistant Bacteria Gut Colonization in Patients with Recurrent Clostridioides difficile Infection from the Open-Label PUNCH CD Study

| PRJNA674880 | ENA

Mucosal gene expression profiling in ileum of patients with Crohn's disease

Project description:In this study, we investigated gene expression profiles in ileal mucosa from CD patients in different settings (post-operative CD (Rutgeerts score i0); post-operative recurrent CD (i1), post-operative recurrent CD (≥i2b), newly diagnosed CD and late stage CD)) and controls.

2019-03-01 | GSE102133 | GEO

Mucosal miRNA expression profiling in ileum of patients with Crohn's disease

Project description:In this study, we investigated miRNA expression profiles in ileal mucosa from CD patients in different settings (post-operative recurrent (POR) CD, newly diagnosed CD and late stage CD)) and controls.

2019-03-01 | GSE102127 | GEO

The Clinical and Molecular Rersponse of Pyoderma Gangrenosum to Interleukin 23 Blockade: results from a proof-of-concept open-label clinical trial

Project description:Open Label Clinical Trial

2024-07-09 | GSE271627 | GEO

Time-restricted feeding prevents deleterious metabolic effects of circadian disruption through epigenetic control of β-cell function [scATAC-seq]

Project description:Circadian rhythm disruption (CD) is associated with dysregulation of glucose homeostasis and Type 2 diabetes mellitus (T2DM). While the link between CD and T2DM remains unclear, there is accumulating evidence that disruption of fasting/feeding cycles mediates CD-induced metabolic dysfunction. Herein we utilized an approach encompassing analysis of behavioral, physiological, transcriptomic, and single-cell epigenomic effects of CD and consequences of restoration of fasting/feeding cycles through time-restricted feeding (tRF) in mice. Results show that CD perturbs glucose homeostasis through disruption of pancreatic β-cell function and loss of circadian β-cell transcriptional and epigenetic control. In contrast, restoration of fasting/feeding cycle prevented CD-mediated metabolic dysfunction by reestablishing circadian regulation of glucose tolerance, β-cell function, β-cell transcriptional profile, and reestablishment of proline and acidic amino acid-rich basic leucine zipper (PAR-bZIP) transcription factor activity in β-cells. This study provides mechanistic insights into beneficial effects of tRF and its role in prevention of β-cell failure in T2DM.

2021-11-24 | GSE182937 | GEO

Time-restricted feeding prevents deleterious metabolic effects of circadian disruption through epigenetic control of β-cell function [ATACseq]

2021-11-24 | GSE182936 | GEO

Time-restricted feeding prevents deleterious metabolic effects of circadian disruption through epigenetic control of β-cell function [ChIPseq]

2021-11-24 | GSE182933 | GEO

Time-restricted feeding prevents deleterious metabolic effects of circadian disruption through epigenetic control of β-cell function [RNAseq]

2021-11-24 | GSE182931 | GEO

Early introduction of oral paricalcitol in renal transplant recipients

Project description:In stable renal transplant recipients with hyperparathyroidism, the vitamin D agonist paricalcitol reduces the level of proteinuria. Animal studies have indicated possible anti-fibrotic and anti-inflammatory effects of paricalcitol. We hypothesised that early introduction of paricalcitol in de novo renal transplant recipients would reduce proteinuria and counteract development of fibrosis in the allograft. A single centre, prospective, randomized, open label trial investigating the additional effect of paricalcitol 2ug/day to standard care was performed. Participants were included 8 weeks after engraftment irrespective of PTH-level and followed for 44 weeks. Microarray analyses were performed in kidney biopsies at study end for the investigation of potential effects on gene expression profile. This dataset is part of the TransQST collection.

2017-09-01 | E-GEOD-83486 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data